The Lancet. Digital health:或许可以提前9年发现是否会罹患阿尔兹海默病

2022-03-05 影像小生 MedSci原创

该研究使得建立阿尔茨海默病诊断前风险因素的可能轨迹成为可能,为预防阿尔茨海默病的可能窗口提供了新的见解。

阿尔茨海默病占全世界痴呆症病例的60 - 70%,因此是21世纪主要的健康挑战之一。2015年,痴呆症影响了10500万欧洲人,预计到2030年,将有13500万欧洲人受到影响。据估计,目前欧洲65岁以上的老年人中有4.5%患有阿尔茨海默氏症(和6.4%患有痴呆症)。阿尔茨海默病在个人和社会层面上都有重大后果,因为它需要高度的社会关怀。识别阿尔茨海默病的可改变风险因素对于早期预防和新干预措施的目标至关重要。

Stanley Durrleman等在The Lancet. Digital health杂志发表研究文章Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records,评估初级保健中诊断出的健康状况与阿尔茨海默病发病风险之间的关联。

对于每个阿尔茨海默病病例,在匹配最后一次访问的性别和年龄后随机分配一个对照。通过运行条件逻辑回归来解释病例和对照的匹配,不可知地测试了从健康记录中提取的国际疾病分类第 10 版的 123 种不同诊断与阿尔茨海默病之间的关联。该研究专注于诊断阿尔茨海默病之前的三个时间段,从早期症状和合并症中分离危险因素。

该研究估计了阿尔茨海默病与各种健康状况之间关联的未调整优势比 (OR) 和 95% CI,并对 p 值进行了多重比较校正。

在英国和法国的研究中,在阿尔茨海默病诊断前 2-10 年的暴露窗口中,十种健康状况与阿尔茨海默病风险增加显着正相关,包括重度抑郁症(UK OR 1·34, 95% CI 1·23–1·46;法国 OR 1·73, 1·57–1·91),焦虑症(英国 OR 1·36, 1·25–1·47;法国 OR 1·50, 1·36–1 ·65),对严重压力和适应障碍的反应(UK OR 1·40, 1·24–1·59;法国 OR 1·83, 1·55–2·15),听力丧失(UK OR 1·19, 1·11–1·28;法国 OR 1·51, 1·21–1·89),便秘(英国 OR 1·31, 1·22–1·41;法国 OR 1·59, 1·44–1 ·75), 脊椎病 (UK OR 1·26, 1·14–1·39; 法国 OR 1·62, 1·44–1·81),体重异常减轻(英国 OR 1·47, 1·33–1·63;法国 OR 1·88, 1·56–2·26),不适和疲劳(英国或 1·23、1·14–1·32;法国或 1·59、1·46–1·73)、记忆力减退(英国或 7·63、6·65–8·76;法国或4·41, 3·07–6·34),晕厥和虚脱(英国 OR 1·23, 1·10–1·37;法国 OR 1·57, 1·26–1·96)。

诊断前2-10年内与未来阿尔茨海默病诊断相关的健康状况

多变量分析后,5种症状仍然显著相关,包括焦虑、抑郁症、便秘、脊椎病和记忆力减退。

在确诊前10-15年的时间窗内,则没有发现上述症状与阿尔茨海默病确诊显著有关。

在确诊前0-2年,共有21种症状与阿尔茨海默病确诊显著有关可能是阿尔茨海默病的合并症状,包括上述除脊椎病外的9种症状,以及甲状腺功能减退、睡眠障碍、脑血管疾病、低血压、腹股沟疝、背痛、其他泌尿系统疾病、尿失禁、夜尿、头晕和眩晕、前臂骨折、骨折等12种症状。

研究团队对比了阿尔茨海默病相关的多种健康问题发病率随时间的变化,发现抑郁症是与阿尔茨海默病相关的第一个合并症,至少在首次临床诊断前9 年就已出现,其次是焦虑、便秘和体重异常减轻,在诊断前约7年时普遍出现。

与随后的阿尔茨海默病诊断显著相关的共病情况的发生率

在与阿尔茨海默病显著相关的健康状况队列中,发病率随时间的变化

这些来自两个独立初级保健数据库的结果提供了关于风险因素的时间性和阿尔茨海默病早期迹象的新证据,这些迹象在全科医生层面是可以观察到的。这些结果可以指导新的一级和二级预防政策的实施。该研究使得建立阿尔茨海默病诊断前风险因素的可能轨迹成为可能,为预防阿尔茨海默病的可能窗口提供了新的见解。

原文出处

Nedelec, Thomas et al. “Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records.” The Lancet. Digital health vol. 4,3 (2022): e169-e178. doi:10.1016/S2589-7500(21)00275-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1861491, encodeId=a378186149106, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Mar 25 03:51:18 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784338, encodeId=61ca1e84338f8, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Mon Mar 07 19:51:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831479, encodeId=7fcf18314e995, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 11:51:18 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402844, encodeId=fdf81402844ef, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621944, encodeId=972a162194407, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-25 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1861491, encodeId=a378186149106, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Mar 25 03:51:18 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784338, encodeId=61ca1e84338f8, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Mon Mar 07 19:51:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831479, encodeId=7fcf18314e995, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 11:51:18 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402844, encodeId=fdf81402844ef, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621944, encodeId=972a162194407, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-07 venlin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1861491, encodeId=a378186149106, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Mar 25 03:51:18 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784338, encodeId=61ca1e84338f8, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Mon Mar 07 19:51:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831479, encodeId=7fcf18314e995, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 11:51:18 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402844, encodeId=fdf81402844ef, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621944, encodeId=972a162194407, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-10-11 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1861491, encodeId=a378186149106, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Mar 25 03:51:18 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784338, encodeId=61ca1e84338f8, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Mon Mar 07 19:51:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831479, encodeId=7fcf18314e995, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 11:51:18 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402844, encodeId=fdf81402844ef, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621944, encodeId=972a162194407, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1861491, encodeId=a378186149106, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Fri Mar 25 03:51:18 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784338, encodeId=61ca1e84338f8, content=<a href='/topic/show?id=98275961cd' target=_blank style='color:#2F92EE;'>#digital#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5961, encryptionId=98275961cd, topicName=digital)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aae2431, createdName=venlin, createdTime=Mon Mar 07 19:51:18 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831479, encodeId=7fcf18314e995, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Oct 11 11:51:18 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402844, encodeId=fdf81402844ef, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621944, encodeId=972a162194407, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Mar 02 14:51:18 CST 2022, time=2022-03-02, status=1, ipAttribution=)]

相关资讯

J Pediatr:练肌肉要从娃娃抓起!美研究发现,握力弱的青少年未来健康状况较差

美国贝勒大学Paul M. Gordon等发表的一项研究表明,握力或可用来预测青少年的心脏代谢风险,握力较弱者未来健康状况较差。

JAMA Cardiol:经导管二尖瓣修复与30天和1年生活质量结局的关联

在这个接受缘对缘TMVR的全国性美国患者队列中,患者术前健康状况受损,并在30天内改善,有可用数据的存活患者在1年内健康状态保持稳定。

我不要你觉得,我要我觉得!即使自评,有心理困扰的乳腺癌患者生存时间缩短28年!死亡风险上升45%!

PLoS One.:评估美国乳腺癌患者自我报告的心理痛苦和自我评估的健康状况与生存时间的关系

因肥丧命!肥胖让人平均减寿3年,儿童和青少年受影响最恶劣

经济合作与发展组织(OECD)发布最新报告《肥胖重负:预防经济学》(以下简称《肥胖重负》)称,世界多国急需“瘦身”。若不加以控制,到2050年,世界发达国家、富裕地区的人均寿命,或将减少3年,可能有9000万人“因肥丧命”。

研究:新冠病毒可破坏血脑屏障

新冠病毒感染症状多样,呼吸道症状是其主要表现,还有一些患者症状指向血管炎症。一个美国研究团队最新发现,新冠病毒还能让血脑屏障出现“漏洞”,潜在破坏大脑神经网络。

Sci Trans Med:步行方式变化可预测死亡和残疾

近日,Science Translational Medicine发表的一项研究指出,步行方式的改变可预测哪些老年人衰弱、残疾和死亡的风险最高。自发性日常运动的变量特征有助于监测老年人的健康状况。